BIOMARIN PHARMACEUTICAL ($BMRN) posted quarterly earnings results for Q3 2026 on Monday, November 2nd. The company reported earnings of $0.23 per share, beating estimates of $0.12 by $0.11. The company also reported revenue of $1,024,650,000, missing estimates of $1,046,694,624 by $-22,044,624.
Stock price change since market close: -5.99%
You can see Quiver Quantitative's $BMRN stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIOMARIN PHARMACEUTICAL Insider Trading Activity
BIOMARIN PHARMACEUTICAL insiders have traded $BMRN stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BMRN stock by insiders over the last 6 months:
- GEORGE ERIC DAVIS (EVP, Chief Legal Officer) sold 17,557 shares for an estimated $1,163,748
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
BIOMARIN PHARMACEUTICAL Hedge Fund Activity
We have seen 278 institutional investors add shares of BIOMARIN PHARMACEUTICAL stock to their portfolio, and 268 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VESTAL POINT CAPITAL, LP added 2,450,000 shares (+68.5%) to their portfolio in Q2 2026, for an estimated $140,189,000
- DEEP TRACK CAPITAL, LP added 2,157,481 shares (+187.6%) to their portfolio in Q2 2026, for an estimated $123,451,062
- AQR CAPITAL MANAGEMENT LLC removed 1,977,000 shares (-25.8%) from their portfolio in Q2 2026, for an estimated $113,123,940
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,616,020 shares (+inf%) to their portfolio in Q2 2026, for an estimated $92,468,664
- DEERFIELD MANAGEMENT COMPANY, L.P. added 1,332,836 shares (+inf%) to their portfolio in Q2 2026, for an estimated $76,264,875
- FMR LLC added 1,255,862 shares (+35.2%) to their portfolio in Q2 2026, for an estimated $71,860,423
- POINT72 ASSET MANAGEMENT, L.P. removed 1,199,206 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $68,618,567
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
BIOMARIN PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $BMRN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Canaccord Genuity issued a "Buy" rating on 05/22/2026
To track analyst ratings and price targets for BIOMARIN PHARMACEUTICAL, check out Quiver Quantitative's $BMRN forecast page.
BIOMARIN PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $BMRN recently. We have seen 6 analysts offer price targets for $BMRN in the last 6 months, with a median target of $72.0.
Here are some recent targets:
- Luca Issi from RBC Capital set a target price of $62.0 on 07/07/2026
- Whitney Ijem from Canaccord Genuity set a target price of $111.0 on 05/22/2026
- Eric Joseph from Citigroup set a target price of $75.0 on 05/19/2026
- Jason Zemansky from B of A Securities set a target price of $80.0 on 05/19/2026
- Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $50.0 on 05/18/2026
- Salveen Richter from Goldman Sachs set a target price of $69.0 on 05/11/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
